Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02520713
Other study ID # 15-169
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date October 2015
Est. completion date October 2025

Study information

Verified date January 2024
Source Dana-Farber Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling. The tumor profiling may result in identifying changes in genes of the tumor that indicate that a particular therapy may have activity. This is called an individualized cancer therapy (iCat) recommendation. The results of the tumor profiling and, if applicable, the iCat recommendation will be returned.


Description:

Patients with extra-cranial (not in the brain) solid tumors that are either difficult to diagnose or more difficult to treat are eligible to participate in this study. All enrolled patients will have targeted sequencing of tumor performed. Sequencing results will be reviewed for clinically significant findings including determination of whether any mutations exist that suggest potential for activity of a targeted therapy (iCat recommendation). Results will be returned to the patient's oncologist and follow-up data will be collected. In this prospective multi-center cohort study, the primary objective is to describe the outcomes of pediatric patients with advanced solid tumors according to whether or not they received of targeted therapy matched to an iCat recommendation. The primary clinical outcome of interest is the endpoint of overall survival (OS), with progression-free survival and response rate (RR) as key secondary clinical outcome measures. To address this hypothesis, 825 patients will enroll from an anticipated 11 participating institutions over 3 years.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 825
Est. completion date October 2025
Est. primary completion date January 2024
Accepts healthy volunteers No
Gender All
Age group N/A to 30 Years
Eligibility Inclusion Criteria: - Age -- Age = 30 years at time of initial qualifying solid tumor diagnosis - Diagnosis -- Histologic diagnosis of solid malignancy (excluding brain tumors and lymphoma) that meets at least one of the following criteria: - Refractory, defined as tumor progression after initiation of standard first line therapy without having achieved a prior partial or complete remission OR Biopsy proven residual disease at the completion of planned standard initial front-line therapy. - Recurrent, defined as tumor progression after achieving a prior partial or complete remission - Newly diagnosed high risk disease, defined as having an expected event free survival of < 50% at 2 years. - Lacks definitive diagnosis or classical genomic findings after histologic review and standard molecular testing (rare tumor group). - Examples include (eligibility not limited to these examples): - Histology typically associated with a fusion in which fusion is not detected. - Ewing-like sarcoma - Undifferentiated sarcoma - Inflammatory myofibroblastic tumor without ALK fusion - Infantile fibrosarcoma without NTRK fusion - Specimen Samples - Sufficient tumor specimen available to meet the minimum requirements for profiling from diagnosis or progression / recurrence --- OR - Surgery / biopsy planned as part of clinical care that is anticipated to yield sufficient material to meet the minimum requirements for profiling; OR - Patient has already had molecular profiling and patient has not yet started matched targeted therapy based on the report . Exclusion Criteria: - No Therapy Planned -- Patients who have declined further anticancer therapy will be excluded. - Performance Status -- Patients with Lansky (age < 16 years) or Karnofsky (age =16 years) score < 50 will be excluded. - Life Expectancy -- Patients with anticipated life expectancy < 3 months will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
Genetic testing and GAIN report
All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.

Locations

Country Name City State
United States Children's Hospital Colorado Aurora Colorado
United States Boston Children's Hospital Boston Massachusetts
United States Dana-Farber Cancer Institute Boston Massachusetts
United States University of Chicago Comer Children's Hospital Chicago Illinois
United States Nationwide Children's Hospital Columbus Ohio
United States University of Texas Southwestern Medical Center at Dallas Dallas Texas
United States Columbia University Medical Center New York New York
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States University of Utah Childrens Medical Center Salt Lake City Utah
United States University of California San Francisco San Francisco California
United States Seattle Children's Hospital Seattle Washington
United States Children's National Medical Center Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival In pediatric patients with recurrent or refractory solid tumors who undergo successful molecular profiling, a) to describe the overall survival of patients by treatment group (iCatM, iCatUM and UM); b) to identify demographic, clinical, and genomic factors associated with overall survival from the time of relapse/progression (OSr); and c)to store tumor material, derived cell lines / xenografts, and blood samples for general sample banking and potential future research. 18 months
Secondary Identification of the patient, clinical, and medication access factors associated with a) having an iCat recommendation and b) with receipt of matched targeted therapy. 2 Years
Secondary Determination of factors associated with response and progression-free survival time by treatment group for patients with recurrent/refractory disease and measurable/evaluable disease. 2 Years
Secondary Description of the frequency and range of molecular alterations in pediatric solid tumors at diagnosis and at relapse including a comparison of potentially targetable variants in paired tumor samples obtained from relapse and at initial diagnosis. 2 Years
Secondary Determination of whether participation in a genomics study provides psychological well-being and whether that is associated with level of genomic comprehension and with receipt of an iCat recommendation. 2 Years
See also
  Status Clinical Trial Phase
Recruiting NCT05151718 - Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents
Recruiting NCT02787876 - Pegteograstim in Children With Solid Tumors Phase 2
Recruiting NCT04222413 - Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Phase 1
Recruiting NCT05620862 - Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors Phase 1
Recruiting NCT05468359 - Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients Phase 1/Phase 2
Completed NCT04944875 - Effects of Music and Maternal Voice on Sedation Depth and Sedative Use During Pediatric Magnetic Resonance Imaging. N/A
Recruiting NCT03618381 - EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Phase 1
Recruiting NCT04897321 - B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Phase 1
Completed NCT05024331 - A Prediction Model of Hematological Recovery After High-dose Chemotherapy in Pediatric Solid Tumor
Active, not recruiting NCT04483778 - B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Phase 1
Active, not recruiting NCT04239040 - GVAX Plus Checkpoint Blockade in Neuroblastoma Phase 1
Recruiting NCT03739827 - Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Recruiting NCT02339753 - Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT03222258 - Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
Completed NCT02564198 - A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Phase 1
Recruiting NCT03273829 - Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed or Refractory Solid Tumors and Leukemias Phase 1
Completed NCT03455140 - A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) Phase 1/Phase 2
Completed NCT01853345 - iCAT for Recurrent/Refractory/HR Solid Tumors N/A
Active, not recruiting NCT03478462 - Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma Phase 1
Not yet recruiting NCT05322187 - Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy Phase 2/Phase 3